General
Preferred name
SELINEXOR
Synonyms
KPT-330 ()
ATG-010 ()
Selinexor (KPT-330) ()
CS-2185KPT-330 ()
Xpovio ()
Nexpovio ()
P&D ID
PD010381
CAS
1393477-72-9
Tags
available
molecular glue
covalent binder
drug
Approved by
FDA
EMA
First approval
2019
Drug indication
Recurrent glioblastoma
Acute myeloid leukaemia
Diffuse large B-cell lymphoma
Multiple myeloma
Solid tumour/cancer
Melanoma
Liposarcoma
Neuroendocrine cancer
Drug Status
approved
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Selinexor (KPT-330) is an inhibitor of the nuclear export protein XPO1 (a.k.a. exportin 1) that is being developed as an anti-neoplastic agent by Karyopharm Therapeutics. It is a first-in-class inhibitor that exploits a novel mechanism of action compared to existing chemotherapeutics . The chemical structure is claimed in patent WO2013019561A1 (as compound 70) .
(GtoPdb)
DESCRIPTION
Selinexor (KPT-330), analog of KPT-185, is an orally bioavailable and selective CRM1 inhibitor[1][2].
PRICE
114
DESCRIPTION
Selinexor (KPT-330) is a small molecule inhibitor of CRM1 with selective and oral activity. Selinexor blocks the cell cycle, induces apoptosis, and has antitumor activity for the treatment of multiple myeloma.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
7
Organisms
0
Compound Sets
22
AdooQ Bioactive Compound Library
Axon Medchem Screening Library
ChEMBL Approved Drugs
ChEMBL Drugs
CovBinderInPDB
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
Guide to Pharmacology
Mcule NIBR MoA Box Subset
MedChem Express Bioactive Compound Library
MolGlueDB
NCATS Inxight Approved Drugs
NIH Approved Oncology Drugs
Novartis Chemogenetic Library (NIBR MoA Box)
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
24
Molecular Weight
443.09
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
2
Rotatable Bonds
5
Ring Count
3
Aromatic Ring Count
3
cLogP
3.39
TPSA
97.62
Fraction CSP3
0.12
Chiral centers
0.0
Largest ring
6.0
QED
0.36
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
CRM1
XPO1
XPO1/CRM1 inhibitor
Member status
member
MOA
Exportin 1 inhibitor
exportin antagonist
Indication
multiple myeloma
Pathway
Membrane Transporter/Ion Channel
Source data
